| 0 (0%) | 12-27 02:21 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.47 | 1-year : | 1.66 |
| Resists | First : | 1.26 | Second : | 1.42 |
| Pivot price | 1.1  |
|||
| Supports | First : | 1 | Second : | 0.83 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 1.15 |
| MA(100) : | 1.83 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.4 |
D(3) : | 10.6 |
| RSI | RSI(14): 36.3 |
|||
| 52-week | High : | 9.78 | Low : | 0.96 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PHIO ] has closed above bottom band by 38.9%. Bollinger Bands are 47.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.09 | 1.09 - 1.09 |
| Low: | 1.02 - 1.02 | 1.02 - 1.03 |
| Close: | 1.07 - 1.08 | 1.08 - 1.09 |
Wed, 24 Dec 2025
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - TMX Newsfile
Wed, 24 Dec 2025
Phio To Commence A Toxicology Study For PH-762; Initiatives Underway For A Viable Product In 2026 - Nasdaq
Tue, 23 Dec 2025
Phio Advances PH-762 With FDA-Backed Toxicology Study - TipRanks
Tue, 23 Dec 2025
Phio to begin FDA-required toxicology study for cancer drug PH-762 - Investing.com
Tue, 23 Dec 2025
Phio Pharmaceuticals Corp to begin toxicology study for PH-762 before human trials - SEC filing - marketscreener.com
Tue, 23 Dec 2025
Early PH-762 skin cancer trial sees full tumor clearance in some patients - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 11 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 7.2 (%) |
| Shares Short | 249 (K) |
| Shares Short P.Month | 232 (K) |
| EPS | -2.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -60.2 % |
| Return on Equity (ttm) | -107.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.39 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.51 |
| PEG Ratio | 0 |
| Price to Book value | 0.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|